OTIC - Here Is Otonomy
If you are of the fallen angel school of biotech investing, Otonomy (OTIC) is worth a listen. If you are wary of falling knives, not so much. Although some may see it as an interesting speculation, I am taking a pass on this one for the time being. I set out my thinking below.
Back in 2017, Otonomy had a great fall, not like September in Maine, but like Humpty Dumpty
As shown by the cliff in the middle of the chart below, Otonomy's travails began on 8/30/2017 when its AVERTS-1 Phase 3